癌基因c-Src抑制剂对三阴性乳腺癌的疗效评价

目的：探讨癌基因C-Src抑制剂对三阴性乳腺癌的辅助治疗作用。方法体外培养三阴性乳腺癌细胞 MDA-MB-231，并与雌激素受体（ER）、孕激素受体（PR）阳性的乳腺癌细胞 T47D 以及HER2阳性的SK-Br-3细胞做比较。用癌基因 c-Src 抑制剂来治疗三株细胞。采用 MTT 和免疫电泳的方法检测细胞的生长以及细胞信号传导通路的改变。结果c-Src抑制剂可以部分抑制 T47D 细胞生长，对三阴性乳腺癌细胞 MDA-MB-231有很明显的抑制作用。但是，对 SK-Br-3细胞的生长没有阻滞作用。进一步研究发现，是否抑制细胞生长信号传导通路决定 c-Src 抑制剂的治疗效果。HER2抑制剂可以明显抑制 SK-Br-3细胞周期与生长，而对 MDA-MB-231没有效果。结论抑制癌基因c-Src酪氨酸激酶活性对三阴性乳腺癌细胞有很好的治疗效果。

Discussion of the therapeutic effects of oncogene c-Src inhibitor on the triple negative breast cancer

Objective To explore adjuvant therapy on triple negative breast cancer （TNBC）.Methods Develop triple negative breast cancer cell MDA-MB-231 cells,comparing with estrogen receptor （ER）and pro-gesterone receptor （PR）positive T47D cells,and HER2 positive Sk-Br-3 cells.They were treated with the in-hibitor of oncogene c-Src.MTT assay was used to measure cell growth.MTT and immunoelectrophoresis were performed to detect the growth of cells and the change of its signaling pathways.Results The c-Src inhibitor partially inhibited cell growth in T47D.It significantly abolished cell proliferation in triple negative MDA-MB-231 cells.However,it has no inhibitory effect on Sk-Br-3 cells.It was found that therapeutic effects of the c-Src inhibitor were related with the blocking cell growth signaling pathways in different cell lines.The HER2 in-hibitor significantly blocked S phase of cell cycles and cell growth in Sk-Br-3 cells,without any effect on MDA-MB-231 cells.Conclusions Inhibition of the tyrosine kinase activity of c-Src is an effective therapy to treat tri-ple negative breast cancer cells.